Download PDF
Dtsch Med Wochenschr 2017; 142(04): 276-281
DOI: 10.1055/s-0042-121855
Kasuistik
© Georg Thieme Verlag KG Stuttgart · New York

Kathetertherapie der hypertroph-obstruktiven Kardiomyopathie: Langzeitverlauf 1996–2016

Catheter-Based Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Long-Term Follow-Up 1996–2016
Lothar Faber
1   Klinik für Kardiologie, Herz- und Diabeteszentrum NRW, Klinik der Ruhr-Universität Bochum, Bad Oeynhausen
,
Ulrich Gleichmann
1   Klinik für Kardiologie, Herz- und Diabeteszentrum NRW, Klinik der Ruhr-Universität Bochum, Bad Oeynhausen
,
Dieter Horstkotte
1   Klinik für Kardiologie, Herz- und Diabeteszentrum NRW, Klinik der Ruhr-Universität Bochum, Bad Oeynhausen
,
Hubert Seggewiss
2   Medizinische Klinik, Leopoldina-Krankenhaus Schweinfurt
› Author Affiliations
Further Information

Publication History

Publication Date:
24 February 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Seit der Erstpublikation im Jahr 1995 hat die katheterbasierte Ablation des subaortalen Septums (Akronyme alphabetisch sortiert u. a.: ASA, ESA, NSMR, PTSMA, TASH) für medikamentös therapierefraktäre Patienten mit hypertroph-obstruktiver Kardiomyopathie (HOCM) ihren Weg gemacht von einer kleinen Fallserie bis in die Leitlinien für diese Erkrankung. Wir berichten nachfolgend über den Langzeitverlauf (20 Jahre) bei den ersten sechs Anfang 1996 in unserer Klinik erfolgreich behandelten und in dieser Wochenschrift publizierten Patienten.

Abstract

Since the first publication in 1995 percutaneous septal ablation (acronyms in alphabetical order: ASA, ESA, NSMR, PTSMA, TASH, among others) has made its way from a small case series into the international guidelines for patients with HOCM and symptoms not responding to medical treatment. We now report on the long-term course (20 years) in the first 6 cases who were successfully treated in our institution in early 1996, published in this Journal shortly thereafter.

Schlüsselwörter

HCM - HOCM - Septumablation - Kathetertherapie - PTSMA

Key words

HCM - HOCM - septal ablation - catheter therapy - PTSMA
 

  • Literatur

  • 1 Grüntzig A. Senning A. Siegenthaler WE. Nonoperative Dilatation of Coronary Artery Stenosis: Percutaneous Transluminal Coronary Angioplasty. N Engl J Med 1979; 301: 61-68
    CrossrefPubMedGoogle Scholar
  • 2 Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214
    CrossrefPubMedGoogle Scholar
  • 3 Gleichmann U. Seggewiss H. Faber L. et al. Kathetertherapie der HOCM. Dtsch Med Wochenschr 1996; 121: 679-685
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Elliott PM. Anastasakis A. Borger MA. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35: 2733-2379
    CrossrefPubMedGoogle Scholar
  • 5 Gersh BJ. Maron BJ. Bonow RO. et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2011; 58: 212-260
    PubMedGoogle Scholar
  • 6 Faber L. Seggewiss H. Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intra-procedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-2421
    CrossrefPubMedGoogle Scholar
  • 7 Alcalai R. Seidman JG. Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008; 19: 104-110
    PubMedGoogle Scholar
  • 8 Losi MA. Betocchi S. Barbati G. et al. Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009; 22: 76-81
    CrossrefPubMedGoogle Scholar
  • 9 Maron MS. Olivotto I. Zenovich AG. et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114: 2232-2239
    Google Scholar
  • 10 Nistri S. Olivotto I. Maron MS. et al. β blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am J Cardiol 2012; 110: 715-719
    CrossrefPubMedGoogle Scholar
  • 11 Morrow AG. Reitz BA. Epstein SE. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975; 52: 88-102
    CrossrefPubMedGoogle Scholar
  • 12 Schulte HD. Gramsch-Zabel H. Schwartzkopff B. Hypertrophische obstruktive Kardiomyopathie: Chirurgische Behandlung. Schweiz Med Wochenschr 1995; 125: 1940-1949
    PubMedGoogle Scholar
  • 13 Faber L. Welge D. Fassbender D. et al. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: Managing the risk of procedure-related AV conduction disturbances. Int J Cardiol 2007; 119: 163-167
    CrossrefPubMedGoogle Scholar
  • 14 Jensen MK. Prinz C. Horstkotte D. et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 2013; 99: 1012-1017
    CrossrefPubMedGoogle Scholar
  • 15 Veselka J. Jensen MK. Liebregts M. et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J 2016; 37: 1517-1523
    CrossrefPubMedGoogle Scholar
  • 16 Maron BJ. Spirito P. Shen W-K. et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405-412
    PubMedGoogle Scholar